| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | VACWR156 |
| Uniprot No | P68617 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 57-185aa |
| 氨基酸序列 | VRLNQCMSANEAAITDAAVAVAAASSTHRKVASSTTQYDHKESCNGLYYQGSCYILHSDYQLFSDAKANCTAESSTLPNKSDVLITWLIDYVEDTWGSDGNPITKTTSDYQDSDVSQEVRKYFCVKTMN |
| 预测分子量 | 16.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VACWR156重组蛋白的模拟参考文献示例(基于典型研究主题，非真实文献)：
---
1. **标题**：Structural Characterization of VACWR156 Recombinant Protein in Vaccinia Virus Assembly
**作者**：Zhang Y. et al.
**摘要**：本研究通过大肠杆菌表达系统纯化了VACWR156重组蛋白，并利用X射线晶体学解析其三维结构。结果表明，VACWR156在痘苗病毒粒子组装中可能与宿主细胞膜相互作用，为揭示病毒出芽机制提供新见解。
2. **标题**：Immunogenicity Evaluation of VACWR156 as a Potential Vaccine Adjuvant
**作者**：Smith J.R. et al.
**摘要**：研究在小鼠模型中评估了VACWR156重组蛋白的免疫增强效果。实验显示，该蛋白可显著提高抗原特异性抗体和T细胞反应，提示其在新型疫苗佐剂开发中的潜力。
3. **标题**：Functional Analysis of VACWR156 in Viral Immune Evasion
**作者**：Li H. et al.
**摘要**：通过CRISPR敲除技术，发现VACWR156蛋白能够抑制宿主NF-κB信号通路，从而削弱先天免疫应答。该功能可能解释痘苗病毒在感染早期的免疫逃逸策略。
4. **标题**：High-Yield Production of VACWR156 Recombinant Protein Using Baculovirus System
**作者**：García M. et al.
**摘要**：优化了杆状病毒-昆虫细胞表达系统，实现VACWR156的高效可溶性表达。纯化后的蛋白可用于大规模抗体生产及体外受体结合实验，支持后续诊断试剂开发。
---
**注意**：以上文献为模拟示例，实际研究中请通过PubMed、Web of Science或Google Scholar检索关键词“VACWR156 recombinant protein”或相关病毒基因功能研究获取真实文献。
**Background of VACWR156 Recombinant Protein**
VACWR156 is a recombinant protein derived from the vaccinia virus (VACV), a member of the *Poxviridae* family. The vaccinia virus, particularly the Western Reserve (WR) strain, has been extensively studied as a model for poxvirus biology and as a foundational tool in vaccine development, notably for smallpox eradication. The VACWR156 gene encodes a viral protein implicated in host-pathogen interactions, immune modulation, or viral replication processes, though its precise functional role remains under investigation.
Recombinant VACWR156 is typically produced via heterologous expression systems (e.g., *E. coli* or mammalian cell cultures) to enable structural and functional studies. Its production allows researchers to explore its biochemical properties, antigenicity, and potential interactions with host cellular machinery. Such studies are critical for understanding viral pathogenesis and developing antiviral strategies.
Interest in VACWR156 also stems from its potential application in vaccine design or as a diagnostic tool. Poxvirus proteins often serve as targets for neutralizing antibodies or T-cell responses, and recombinant versions can be used to map immune epitopes or evaluate vaccine efficacy. Additionally, studying VACWR156 may shed light on mechanisms of immune evasion, as poxviruses encode numerous proteins that subvert host defense pathways.
While detailed characterization of VACWR156 is ongoing, its inclusion in recombinant form highlights its relevance in virology and immunology research. Further investigations could clarify its role in viral lifecycle stages, such as entry, replication, or assembly, and inform therapeutic interventions against poxviral infections or related emerging pathogens.
(Word count: 245)
×
